Transurethral Therapy for the Treatment of Erectile Dysfunction: Infant or Dinosaur?
Transurethral pharmacotherapy (TUPT) for the treatment of patients with erectile dysfunction has demonstrated moderate efficacy with an excellent safety profile. Unfortunately, the initial clinical efficacy of transurethral alprostadil (TUA) has led to physician and patient dissatisfaction with this treatment regimen. An understanding of the mechanism of TUPT, and a review of the available literature, suggests that improvements in treatment efficacy and local side effects are in the near future.